Preview

Войти

Регистрация нового пользователя Забыли Ваш пароль?

Научно-практическая ревматология

Расширенный поиск

Проблемы системных заболеваний соединительной ткани детского возраста в исторической перспективе

https://doi.org/10.47360/1995-4484-2023-639-649

Аннотация

Актуальность изучения системных заболеваний соединительной ткани с ювенильным началом для современной медицины определяется тенденцией к их росту в популяции, трудностью ранней диагностики, быстрым развитием инвалидности и неблагоприятным жизненным прогнозом. В статье представлены основные достижения в изучении этой группы заболеваний у детей с акцентом на наиболее значимые с практической точки зрения вопросы, связанные с диагностикой, классификацией, особенностями клинической картины и современными подходами к терапии.

Об авторах

М. И. Каледа
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

Каледа Мария Игоревна.

115522, Москва, Каширское шоссе, 34а
Конфликт интересов:

Нет



И. П. Никишина
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

115522, Москва, Каширское шоссе, 34а
Конфликт интересов:

Нет



Список литературы

1. Tarvin SE, O’Neil KM, Systemic lupus erythematosus, Sjögren syndrome, and mixed connective tissue disease in children and adolescents. Pediatr Clin North Am. 2018;65(4):711-737. doi: 10.1016/j.pcl.2018.04.001

2. Klemperer P, Pollack AD, Baehr G. Diffuse collagen disease. Arch Path. 1941;32:569-591.

3. Сигидин ЯА, Иванова ММ, Гусева НГ. Диффузные болезни соединительной ткани (системные ревматические заболевания). Руководство для врачей. М.:Медицина;1994.

4. Лыскина Г.А. Проблемы системных заболеваний соединительной ткани у детей. Педиатрия. Журнал им. Г.Н. Сперанского. 2004;2:46-52.

5. McGonagle D, Aziz A, Dickie LJ, McDermott MF. An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum. Pediatr Res. 2009;65(5 Pt 2):38R-45R. doi: 10.1203/PDR.0b013e31819dbd0a

6. Cui Y, Sheng Y, Zhang X. Genetic susceptibility to SLE: Recent progress from GWAS. J Autoimmun. 2013;41:25-33. doi: 10.1016/j.jaut.2013.01.008

7. Smith EMD, Lythgoe H, Midgley A, Beresford MW, Hedrich CM. Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. Clin Immunol. 2019;209:108274. doi: 10.1016/j.clim.2019.108274

8. Alexander T, Hedrich CM. Systemic lupus erythematosus – Are children miniature adults? Clin Immunol. 2022;234:108907. doi: 10.1016/j.clim.2021.108907

9. Асеева ЕА, Лила АМ, Соловьев СК, Насонов ЕЛ, Глухова СИ. Клинико-иммунологические фенотипы системной красной волчанки, выделенные на основании кластерного анализа данных 400 пациентов ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой». Современная ревматология. 2022;16(5):13-21. doi: 10.14412/1996-7012-2022-5-13-21

10. Groot N, Shaikhani D, Teng YKO, de Leeuw K, Bijl M, Dolhain RJEM, et al. Long-term clinical outcomes in a cohort of adults with childhood-onset systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(2):290-301. doi: 10.1002/art.40697

11. Levy DM, Kamphuis S. Systemic lupus erythematosus in children and adolescents. Pediatr Clin North Am. 2012;59(2):345-364. doi: 10.1016/j.pcl.2012.03.007

12. Huang JL, Yao TC, See LC. Prevalence of pediatric systemic lupus erythematosus and juvenile chronic arthritis in a Chinese population: A nation-wide prospective population-based study in Taiwan. Clin Exp Rheumatol. 2004;22:776-780.

13. Hedrich CM, Smith EMD, Beresford MW. Juvenile-onset systemic lupus erythematosus (jSLE) – Pathophysiological concepts and treatment options. Best Pract Res Clin Rheumatol. 2017;31(4):488-504. doi: 10.1016/j.berh.2018.02.001

14. Ardoin SP, Daly RP, Merzoug L, Tse K, Ardalan K, Arkin L, et al.; Childhood Arthritis and Rheumatology Research Alliance and Lupus Foundation of America. Research priorities in childhood -onset lupus: Results of a multidisciplinary prioritization exercise. Pediatr Rheumatol Online J. 2019;17(1):32. doi: 10.1186/s12969-019-0327-4

15. Appenzeller S, Pereira DR, Julio PR, Reis F, Rittner L, Marini R. Neuropsychiatric manifestations in childhood-onset systemic lupus erythematosus. Lancet Child Adolesc Health. 2022;6(8):571-581. doi: 10.1016/S2352-4642(22)00157-2

16. Natoli V, Charras A, Hahn G, Hedrich CM. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus (jSLE). Mol Cell Pediatr. 2023;10(1):5. doi: 10.1186/s40348-023-00161-7

17. Каледа МИ, Никишина ИП, Глухова СИ, Степаненко НЮ. Нейропсихические нарушения при ювенильном дебюте системной красной волчанки: результаты ретроспективного исследования. Научно-практическая ревматология. 2020;58(2):171-177. doi: 10.14412/1995-4484-2020-171-177

18. Yu H, Nagafuchi Y, Fujio K. Clinical and immunological biomarkers for systemic lupus erythematosus. Biomolecules. 2021;11(7):928. doi: 10.3390/biom11070928

19. Caielli S, Wan Z, Pascual V. Systemic lupus erythematosus pathogenesis: Interferon and beyond. Annu Rev Immunol. 2023;41:533-560. doi: 10.1146/annurev-immunol-101921-042422

20. Li H, Wang T, Li B, Huang T, Hai Y, Huang C, et al. Bioinformatic analysis of immune-related transcriptome affected by IFIT1 gene in childhood systemic lupus erythematosus. Transl Pediatr. 2023;12(8):1517-1526. doi: 10.21037/tp-23-365

21. Sestan M, Kifer N, Arsov T, Cook M, Ellyard J, Vinuesa CG, et al. The role of genetic risk factors in pathogenesis of childhoodonset systemic lupus erythematosus. Curr Issues Mol Biol. 2023;45(7):5981-6002. doi: 10.3390/cimb45070378

22. Massias JS, Smith EMD, Al-Abadi E, Armon K, Bailey K, Ciurtin C, et al. Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. Lupus. 2020;29(5):474-481. doi: 10.1177/0961203320909156

23. Massias JS, Smith EM, Al-Abadi E, Armon K, Bailey K, Ciurtin C, et al. Clinical and laboratory phenotypes in juvenile-onset systemic lupus erythematosus across ethnicities in the UK. Lupus. 2021;30(4):597-607. doi: 10.1177/0961203320984251

24. Lythgoe H, Lj M, Hedrich CM, Aringer M. Classification of systemic lupus erythematosus in children and adults. Clin Immunol. 2022;234:108898. doi: 10.1016/j.clim.2021.108898

25. Chang LS, Huang PY, Kuo HC, Tu YK, Tseng PT, Liang CS, et al. Diagnostic accuracy of the American College of Rheumatology-1997, the Systemic Lupus International Collaborating Clinics-2012, and the European League Against Rheumatism-2019 criteria for juvenile systemic lupus erythematosus: A systematic review and network meta-analysis. Autoimmun Rev. 2022;21(9):103144. doi: 10.1016/j.autrev.2022.103144

26. Falcini F, Nacci F. Systemic lupus erythematosus in the young: The importance of a transition clinic. Lupus. 2007;16(8):613-617. doi: 10.1177/0961203307078973

27. Alperin JM, Ortiz-Fernández L, Sawalha AH. Monogenic lupus: A developing paradigm of disease. Front Immunol. 2018;9:2496. doi: 10.3389/fimmu.2018.02496

28. Harley ITW, Sawalha AH. Systemic lupus erythematosus as a genetic disease. Clin Immunol. 2022;236:108953. doi: 10.1016/j.clim.2022.108953

29. Demirkaya E, Sahin S, Romano M, Zhou Q, Aksentijevich I. New horizons in the genetic etiology of systemic lupus erythematosus and lupus-like disease: Monogenic lupus and beyond. J Clin Med. 2020;9(3):712. doi: 10.3390/jcm9030712

30. Kim H, Sanchez GA, Goldbach-Mansky R. Insights from Mendelian interferonopathies: Comparison of CANDLE, SAVI with AGS, monogenic lupus. J Mol Med (Berl). 2016;94(10):1111-1127. doi: 10.1007/s00109-016-1465-5

31. Nigrovic PA, Lee PY, Hoffman HM. Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach. J Allergy Clin Immunol. 2020;146(5):925-937. doi: 10.1016/j.jaci.2020.08.017

32. Sandling JK, Pucholt P, Hultin Rosenberg L, Farias FHG, Kozyrev SV, Eloranta ML, et al. Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. Ann Rheum Dis. 2021;80(1):109-117. doi: 10.1136/annrheumdis-2020-218636

33. Al-Mayouf SM, Alreefi HA, Alsinan TA, AlSalmi G, AlRowais A, Al-Herz W, et al. Lupus manifestations in children with primary immunodeficiency diseases: Comprehensive phenotypic and genetic features and outcome. Mod Rheumatol. 2021;31(6):1171-1178. doi: 10.1080/14397595.2021.1886627

34. Chan SCW, Lau CS. Systemic lupus erythematosus and immunodeficiency. Rheumatol Immunol Res. 2021;2(3):131-138. doi: 10.2478/rir-2021-0019

35. Ozturk K, Caglayan S, Tanatar A, Baglan E, Yener Otar G, Kavrul Kayaalp G, et al.; PeRA-Research Group. Low disease activity state in juvenile-onset systemic lupus erythematosus. Lupus. 2021;30(13):2144-2150. doi: 10.1177/09612033211054399

36. Nakorn K, Piyaphanee N, Sukharomana M, Pinpatanapong R, Charuvanij S. Outcomes of achieving lupus low disease activity state and damage accrual in childhood-onset systemic lupus erythematosus. Clin Rheumatol. 2023;42(6):1655-1664. doi: 10.1007/s10067-023-06533-8

37. Groot N, de Graeff N, Avcin T, Bader-Meunier B, Brogan P, Dolezalova P, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: The SHARE initiative. Ann Rheum Dis. 2017;76(11):1788-1796. doi: 10.1136/annrheumdis-2016-210960

38. Gutiérrez-Suárez R, Ruperto N, Gastaldi R, Pistorio A, Felici E, Burgos-Vargas R, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 2006;54(9):2989-2996. doi: 10.1002/art.22048

39. Blamires J, Foster M, Napier S, Dickinson A. Experiences and perspectives of children and young people living with childhood -onset systemic lupus erythematosus – An integrative review. Children (Basel). 2023;10(6):1006. doi: 10.3390/children10061006

40. Zulian F. Scleroderma in children. Best Pract Res Clin Rheumatol. 2017;31(4):576-595. doi: 10.1016/j.berh.2018.02.004

41. Herrick AL, Ennis H, Bhushan M, Silman AJ, Baildam EM. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res (Hoboken). 2010;62(2):213-218. doi: 10.1002/acr.20070

42. Beukelman T, Xie F, Foeldvari I. Assessing the prevalence of juvenile systemic sclerosis in childhood using administrative claims data from the United States. J Scleroderma Relat Disord. 2018;3(2):189-190. doi: 10.1177/2397198318763701

43. Martini G, Vittadello F, Kasapçopur O, Magni Manzoni S, Corona F, Duarte-Salazar C, et al.; Juvenile Scleroderma Working Group of Paediatric Rheumatology European Society (PRES). Factors affecting survival in juvenile systemic sclerosis. Rheumatology (Oxford). 2009;48(2):119-222. doi: 10.1093/rheumatology/ken388

44. Valeur NS, Stevens AM, Ferguson MR, Effmann EL, Iyer RS. Multimodality thoracic imaging of juvenile systemic sclerosis: Emphasis on clinical correlation and high-resolution CT of pulmonary fibrosis. AJR Am J Roentgenol. 2015;204(2):408-422. doi: 10.2214/AJR.14.12461

45. Li SC. Scleroderma in children and adolescents: Localized scleroderma and systemic sclerosis. Pediatr Clin North Am. 2018;65(4):757-781. doi: 10.1016/j.pcl.2018.04.002

46. Scalapino K, Arkachaisri T, Lucas M, Fertig N, Helfrich DJ, Londino AV Jr, et al. Childhood onset systemic sclerosis: Classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol. 2006;33(5):1004-1013.

47. Rutkowska-Sak L, Gietka P, Gazda A, Kołodziejczyk B. Juvenile systemic sclerosis – observations of one clinical centre. Reumatologia. 2021;59(6):367-372. doi: 10.5114/reum.2021.112350

48. Céspedes-Cruz AI, Carranza-Muleiro RA, López-Rojas EL, Cruz-Domínguez MP, Espinosa-Gan H, Ramírez-Pérez J, et al. Pulmonary involvement in patients with juvenile systemic sclerosis. Bol Med Hosp Infant Mex. 2021;78(5):385-394. doi: 10.24875/BMHIM.20000301

49. Foeldvari I, Klotsche J, Hinrichs B, Helmus N, Kasapcopur O, Adrovic A, et al. Underdetection of interstitial lung disease in juvenile systemic sclerosis. Arthritis Care Res (Hoboken). 2022;74(3):364-370. doi: 10.1002/acr.24499

50. Apitz C, Girschick H. Systemic sclerosis-associated pulmonary arterial hypertension in children. Cardiovasc Diagn Ther. 2021;11(4):1137-1143. doi: 10.21037/cdt-20-901

51. Adrovic A, Karatemiz G, Esatoglu SN, Yildiz M, Sahin S, Barut K, et al. Juvenile and adult-onset scleroderma: Different clinical phenotypes. Semin Arthritis Rheum. 2023;60:152197. doi: 10.1016/j.semarthrit.2023.152197

52. Foeldvari I, Klotsche J, Torok KS, Kasapcopur O, Adrovic A, Stanevicha V, et al. Are diffuse and limited juvenile systemic sclerosis different in clinical presentation? Clinical characteristics of a juvenile systemic sclerosis cohort. J Scleroderma Relat Disord. 2019;4(1):49-61. doi: 10.1177/2397198318790494

53. Foeldvari I, Klotsche J, Kasapcopur O, Adrovic A, Terreri MT, Sakamoto AP, et al. Gender differences in juvenile systemic sclerosis patients: Results from the international juvenile scleroderma inception cohort. J Scleroderma Relat Disord. 2023;8(2):120-130. doi: 10.1177/23971983221143244

54. Stevens AM, Torok KS, Li SC, Taber SF, Lu TT, Zulian F. Immunopathogenesis of juvenile systemic sclerosis. Front Immunol. 2019;10:1352. doi: 10.3389/fimmu.2019.01352

55. Zulian F, Woo P, Athreya BH, Laxer RM, Medsger TA Jr, Lehman TJ, et al. The Pediatric Rheumatology European Society/ American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum. 2007;57(2):203-212. doi: 10.1002/art.22551

56. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747-1755. doi: 10.1136/annrheumdis-2013-204424

57. Martini G, Foeldvari I, Russo R, Cuttica R, Eberhard A, Ravelli A, et al.; Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society. Systemic sclerosis in childhood: Clinical and immunologic features of 153 patients in an international database. Arthritis Rheum. 2006;54(12):3971-3978. doi: 10.1002/art.22207

58. Foeldvari I, Culpo R, Sperotto F, Anton J, Avcin T, Baildam E, et al. Consensus-based recommendations for the management of juvenile systemic sclerosis. Rheumatology (Oxford). 2021;60(4):1651-1658. doi: 10.1093/rheumatology/keaa584

59. Klotsche J, Torok KS, Kasapcopur O, Adrovic A, Terreri MT, Sakamoto AP, et al. Application and performance of disease activity indices proposed for patients with systemic sclerosis in an international cohort of patients with juvenile systemic sclerosis. J Scleroderma Relat Disord. 2023;8(3):183-191. doi: 10.1177/23971983231164700

60. Beukelman T, Xie F, Foeldvari I. The prevalence of localised scleroderma in childhood assessed in the administrative claims data from the United States. J Scleroderma Relat Disord. 2019;4(1): 77-78. doi: 10.1177/2397198318798588

61. Zulian F, Vallongo C, Woo P, Russo R, Ruperto N, Harper J, et al.; Juvenile Scleroderma Working Group of the Pediatric Rheumatology European Society (PRES). Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005;52(9):2873-2881. doi: 10.1002/art.21264

62. Papadopoulou C, Chew C, Wilkinson MGL, McCann L, Wedderburn LR. Juvenile idiopathic inflammatory myositis: An update on pathophysiology and clinical care. Nat Rev Rheumatol. 2023;19(6):343-362. doi: 10.1038/s41584-023-00967-9

63. Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J. Incidence and prevalence of inflammatory myopathies: A systematic review. Rheumatology (Oxford). 2015;54(1):50-63. doi: 10.1093/rheumatology/keu289

64. Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, et al.; with the Childhood Myositis Heterogeneity Collaborative Study Group. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(1):25-41. doi: 10.1097/MD.0b013e31827f264d

65. Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken). 2010;62(1):63-72. doi: 10.1002/acr.20015

66. Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med. 2016;280(1):24-38. doi: 10.1111/joim.12444

67. Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, et al.; Childhood Myositis Heterogeneity Study Group. Association of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies with DRB1*07:01 and severe myositis in juvenile myositis patients. Arthritis Care Res (Hoboken). 2017;69(7):1088-1094. doi: 10.1002/acr.23113

68. Li D, Tansley SL. Juvenile dermatomyositis – Clinical phenotypes. Curr Rheumatol Rep. 2019;21(12):74. doi: 10.1007/s11926-019-0871-4

69. Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: Significance of early clinical and laboratory features. Arthritis Rheum. 2008;58(11):3585-3592. doi: 10.1002/art.23960

70. Каледа МИ, Никишина ИП, Салугина СО, Федоров ЕС, Арсеньева СВ, Шаповаленко А.Н., и др. Ювенильные идиопатические воспалительные миопатии: результаты открытого одноцентрового ретроспективного исследования. Современная ревматология. 2022;16(4):32-39. doi: 10.14412/1996-7012-2022-4-32-39

71. Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton R, et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr. 2006;148(2):247-253. doi: 10.1016/j.jpeds.2005.10.032

72. Gitiaux C, De Antonio M, Aouizerate J, Gherardi RK, Guilbert T, Barnerias C, Bodemer C, et al. Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis. Rheumatology (Oxford). 2016;55(3):470-479. doi: 10.1093/rheumatology/kev359

73. Papadopoulou C, Hong Y, Krol P, Al Obaidi M, Pilkington C, Wedderburn LR, et al. The vasculopathy of juvenile dermatomyositis: Endothelial injury, hypercoagulability, and increased arterial stiffness. Arthritis Rheumatol. 2021;73(7):1253-1266. doi: 10.1002/art.41639

74. McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, Murray KJ, et al.; Juvenile Dermatomyositis Research Group. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland) – Clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford). 2006; 45(10):1255-1260. doi: 10.1093/rheumatology/kel099

75. Sanner H, Aaløkken TM, Gran JT, Sjaastad I, Johansen B, Flatø B. Pulmonary outcome in juvenile dermatomyositis: A case-control study. Ann Rheum Dis. 2011;70(1):86-91. doi: 10.1136/ard.2010.131433

76. Orandi AB, Baszis KW, Dharnidharka VR, Huber AM, Hoeltzel MF; CARRA Juvenile Myositis subgroup. Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: A survey of pediatric rheumatologists by the Childhood Arthritis and Rheumatology Research Alliance (CARRA). Pediatr Rheumatol Online J. 2017;15(1):71. doi: 10.1186/s12969-017-0199-4

77. Mehta P, Lawrence A, Gupta L, Misra DP, Agarwal V, Misra R, et al. Long-standing and poorly controlled disease in juvenile dermatomyositis is associated with calcinosis: A real-world experience from a low-middle income country. Rheumatol Int. 2023 Jul 5. doi: 10.1007/s00296-023-05377-4

78. Yi BY, Marrs J, Acharya P, Sura A, Cidon M. Risk factors for developing calcinosis in juvenile dermatomyositis: Subcutaneous and myofascial edema in initial magnetic resonance imaging. Rheumatol Int. 2023 Jul 11. doi: 10.1007/s00296-023-05385-4

79. Okiyama N. Clinical features and cutaneous manifestations of juvenile and adult patients of dermatomyositis associated with myositis-specific autoantibodies. J Clin Med. 2021;10(8):1725. doi: 10.3390/jcm10081725

80. Gerami P, Walling HW, Lewis J, Doughty L, Sontheimer RD. A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol. 2007;157(4):637-644. doi: 10.1111/j.1365-2133.2007.08055.x

81. Mamyrova G, Kishi T, Targoff IN, Ehrlich A, Curiel RV, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group. Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. Rheumatology (Oxford). 2018; 57(11):1956-1963. doi: 10.1093/rheumatology/key190

82. Gezgin Yıldırım D, Baglan E, Güngörer V, Yıldız C, Tuncez S, Bülbül M, et al. Comparison of clinical and laboratory features and treatment responses in patients with clinically amyopathic juvenile dermatomyositis and classical juvenile dermatomyositis. Int J Rheum Dis. 2023;26(8):1504-1511. doi: 10.1111/1756-185X.14773

83. Xia J, Jiang G, Jin T, Shen Q, Ma Y, Wang L, et al. Respiratory symptoms as initial manifestations of interstitial lung disease in clinically amyopathic juvenile dermatomyositis: A case report with literature review. BMC Pediatr. 2021;21(1):488. doi: 10.1186/s12887-021-02958-9

84. Kishi T, Tani Y, Okiyama N, Mizuochi K, Ichimura Y, Harigai M, et al. Anti-SAE autoantibody-positive Japanese patient with juvenile dermatomyositis complicated with interstitial lung disease – A case report. Pediatr Rheumatol Online J. 2021;19(1):34. doi: 10.1186/s12969-021-00532-2

85. Abu-Rumeileh S, Marrani E, Maniscalco V, Maccora I, Pagnini I, Mastrolia MV, et al. Lung involvement in juvenile idiopathic inflammatory myopathy: A systematic review. Autoimmun Rev. 2023;22(10):103416. doi: 10.1016/j.autrev.2023.103416

86. Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, et al.; Childhood Myositis Heterogeneity Collaborative Study Group. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(4):223-243. doi: 10.1097/MD.0b013e31829d08f9

87. Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018;20(4): 21. doi: 10.1007/s11926-018-0732-6

88. Binns EL, Moraitis E, Maillard S, Tansley S, McHugh N, Jacques TS, et al.; UK Juvenile Dermatomyositis Research Group (UK and Ireland). Effective induction therapy for anti-SRP associated myositis in childhood: A small case series and review of the literature. Pediatr Rheumatol Online J. 2017;15(1):77. doi: 10.1186/s12969-017-0205-x

89. Wedderburn LR, McHugh NJ, Chinoy H, Cooper RG, Salway F, Ollier WE, et al.; Juvenile Dermatomyositis Research Group (JDRG). HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford). 2007;46(12):1786-1791. doi: 10.1093/rheumatology/kem265

90. Bitencourt N, Solow EB, Wright T, Bermas BL. Inflammatory myositis in systemic lupus erythematosus. Lupus. 2020;29(7):776-781. doi: 10.1177/0961203320918021

91. Martin N, Krol P, Smith S, Murray K, Pilkington CA, Davidson JE, et al.; Juvenile Dermatomyositis Research Group. A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years’ experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. Rheumatology (Oxford). 2011;50(1):137-145. doi: 10.1093/rheumatology/keq261

92. Moneta GM, Pires Marafon D, Marasco E, Rosina S, Verardo M, Fiorillo C, et al. Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features. Arthritis Rheumatol. 2019;71(6):1011-1021. doi: 10.1002/art.40800

93. Wilkinson MGL, Radziszewska A, Wincup C, Ioannou Y, Isenberg DA, Manson JJ, et al. Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies. Rheumatology (Oxford). 2020;59(1):194-204. doi: 10.1093/rheumatology/kez252

94. Piper CJM, Wilkinson MGL, Deakin CT, Otto GW, Dowle S, Duurland CL, et al. CD19+CD24hiCD38hi B cells are expanded in juvenile dermatomyositis and exhibit a pro-inflammatory phenotype after activation through Toll-like receptor 7 and interferon-α. Front Immunol. 2018;9:1372. doi: 10.3389/fimmu.2018.01372

95. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403-407.

96. Brown VE, Pilkington CA, Feldman BM, Davidson JE; Network for juvenile dermatomyositis, Paediatric Rheumatology European Society (PReS). An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford). 2006;45(8):990-993. doi: 10.1093/rheumatology/kel025

97. Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al.; International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017;69(12):2271-2282. doi: 10.1002/art.40320

98. Patel B, Khan N, Werth VP. Applicability of EULAR/ACR classification criteria for dermatomyositis to amyopathic disease. J Am Acad Dermatol. 2018;79(1):77-83.e1. doi: 10.1016/j.jaad.2017.12.055

99. Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329-340. doi: 10.1136/annrheumdis-2016-209247

100. Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/ Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBM-FRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S118-S157. doi: 10.1002/acr.20532

101. Gebreamlak A, Sawicka KM, Garrett R, Goh YI, Baker KM, Feldman BM. Currently recommended skin scores correlate highly in the assessment of patients with juvenile dermatomyositis (JDM). Pediatr Rheumatol Online J. 2023;21(1):63. doi: 10.1186/s12969-023-00844-5

102. Gargh K, Al-Abadi E, Low S, Harrison K, Coles W, Davis P, et al. Juvenile Dermatomyositis Magnetic Resonance Imaging Score (JIS) does not correlate with criteria for clinically inactive disease: A single-centre retrospective evaluation. Rheumatol Int. 2022;42(7):1221-1226. doi: 10.1007/s00296-021-05049-1

103. Kobayashi I, Akioka S, Kobayashi N, Iwata N, Takezaki S, Nakaseko H, et al. Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update. Mod Rheumatol. 2020;30(3):411-423. doi: 10.1080/14397595.2020.1718866

104. Хелковская-Сергеева АН, Ананьева ЛП, Казаков ДО, Насонов ЕЛ. Применение магнитно-резонансной томографии в диагностике идиопатических воспалительных миопатий. Современная ревматология. 2019;13(1):95-100. doi: 10.14412/1996-7012-2019-1-95-100

105. Gao W, Yuan C, Zou Y, Lin H. Development and pilot testing a self-reported pediatric PROMIS app for young children aged 5–7 years. J Pediatr Nurs. 2020;53:74-83. doi: 10.1016/j.pedn.2020.04.003

106. Patel REV, Lai J-S, Gray E, Chang R, Cella D, Ardalan K. Comparison of PROMIS computerized adaptive testing administered item banks vs fixed short forms in juvenil myositis. Arthritis Rheum. 2019;71(10):abstract #433.

107. Li YR, Li J, Zhao SD, Bradfield JP, Mentch FD, Maggadottir SM, et al. Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases. Nat Med. 2015;21(9):1018-1027. doi: 10.1038/nm.3933

108. Molano-González N, Rojas M, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Rodríguez Y, et al. Cluster analysis of autoimmune rheumatic diseases based on autoantibodies. New insights for polyautoimmunity. J Autoimmun. 2019;98:24-32. doi: 10.1016/j.jaut.2018.11.002

109. Malagón C, Gomez MDP, Mosquera C, Vargas C, Gonzalez T, Arango C, et al. Juvenile polyautoimmunity in a rheumatology setting. Autoimmun Rev. 2019;18(4):369-381. doi: 10.1016/j.autrev.2018.11.006

110. Anaya JM, Rojas-Villarraga A, Mantilla RD, Arcos-Burgos M, Sarmiento-Monroy JC. Polyautoimmunity in Sjögren syndrome. Rheum Dis Clin North Am. 2016;42(3):457-472. doi: 10.1016/j.rdc.2016.03.005

111. Каледа МИ, Никишина ИП, Латыпова АН. Синдром Шегрена с дебютом в детском возрасте. Терапевтический архив. 2019; 91(5):54-60. [Kaleda MI, Nikishina IP, Latypova AN. Sjögren’s syndrome with juvenile onset. Terapevticheskii arkhiv. 2019; 91(5):54-60 (In Russ.)]. doi: 10.26442/00403660.2019.05.000189

112. Groot N, de Graeff N, Marks SD, Brogan P, Avcin T, Bader-Meunier B, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: The SHARE initiative. Ann Rheum Dis. 2017;76(12):1965-1973. doi: 10.1136/annrheumdis-2017-211898

113. Ramaswamy M, Tummala R, Streicher K, Nogueira da Costa A, Brohawn PZ. The pathogenesis, molecular mechanisms, and therapeutic potential of the interferon pathway in systemic lupus erythematosus and other autoimmune diseases. Int J Mol Sci. 2021;22(20):11286. doi: 10.3390/ijms222011286

114. Насонов ЕЛ, Решетняк ТМ, Соловьев СК, Попкова ТВ. Системная красная волчанка и антифосфолипидный синдром: вчера, сегодня, завтра. Терапевтический архив. 2023; 95(5):365-374. doi: 10.26442/00403660.2023.05.202246

115. Jansson AF, Sengler C, Kuemmerle-Deschner J, Gruhn B, Kranz AB, Lehmann H, et al. B cell depletion for autoimmune diseases in paediatric patients. Clin Rheumatol. 2011;30(1):87-97. doi: 10.1007/s10067-010-1630-0

116. Werner A, Schäfer S, Zaytseva O, Albert H, Lux A, Krištić J, et al. Targeting B cells in the pre-phase of systemic autoimmunity globally interferes with autoimmune pathology. iScience. 2021;24(9):103076. doi: 10.1016/j.isci.2021.103076

117. Merino-Vico A, Frazzei G, van Hamburg JP, Tas SW. Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches. Eur J Immunol. 2023;53(1):e2149675. doi: 10.1002/eji.202149675

118. Welzel T, Winskill C, Zhang N, Woerner A, Pfister M. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology – What we know and what we do not know from randomized controlled trials. Pediatr Rheumatol Online J. 2021;19(1):46. doi: 10.1186/s12969-021-00514-4

119. Насонов ЕЛ, Бекетова ТВ, Ананьева ЛП, Васильев ВИ, Соловьев СК, Авдеева АС. Перспективы анти-В-клеточной терапии при иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40. doi: 10.14412/1995-4484-2019-3-40

120. Mahmoud I, Jellouli M, Boukhris I, Charfi R, Ben Tekaya A, Saidane O, et al. Efficacy and safety of rituximab in the management of pediatric systemic lupus erythematosus: A systematic review. J Pediatr. 2017;187:213-219.e2. doi: 10.1016/j.jpeds.2017.05.002

121. Sawhney S, Agarwal M. Rituximab use in pediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort. Lupus. 2021;30(11):1829-1836. doi: 10.1177/09612033211034567

122. Zulian F, Dal Pozzolo R, Meneghel A, Castaldi B, Marcolongo R, Caforio ALP, et al. Rituximab for rapidly progressive juvenile systemic sclerosis. Rheumatology (Oxford). 2020;59(12):3793-3797. doi: 10.1093/rheumatology/keaa193

123. Marrani E, Abu-Rumeileh S, Mastrolia MV, Maccora I, Pagnini I, Simonini G. A systematic review on biological therapies in juvenile idiopathic inflammatory myopathies: An evidence gap in precision medicine. Clin Exp Rheumatol. 2022;40(2):457-470. doi: 10.55563/clinexprheumatol/ltrj4l

124. Каледа МИ, Никишина ИП, Николаева ЕВ, Шаповаленко АН, Федоров ЕС, Пачкория ТН. Ритуксимаб при ревматических заболеваниях у детей: результаты ретроспективного исследования безопасности терапии. Научно-практическая ревматология. 2021;59(2):208-214. doi: 10.47360/1995-4484-2021-208-214

125. Насонов ЕЛ, Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-383. doi: 10.47360/1995-4484-2021-367-383

126. Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020;79(10):1340-1348. doi: 10.1136/annrheumdis-2020-217101

127. Curiel RV, Nguyen W, Mamyrova G, Jones D, Ehrlich A, Brindle KA, et al.; Abatacept in Dermatomyositis (AID) Trial Investigators. Improvement in disease activity in refractory juvenile dermatomyositis following abatacept therapy. Arthritis Rheumatol. 2023;75(7):1229-1237. doi: 10.1002/art.42450

128. Kalampokis I, Yi BY, Smidt AC. Abatacept in the treatment of localized scleroderma: A pediatric case series and systematic literature review. Semin Arthritis Rheum. 2020;50(4):645-656. doi: 10.1016/j.semarthrit.2020.03.020

129. Adrovic A, Yildiz M, Haslak F, Koker O, Aliyeva A, Sahin S, et al. Tocilizumab therapy in juvenile systemic sclerosis: a retrospective single centre pilot study. Rheumatol Int. 2021;41(1):121-128. doi: 10.1007/s00296-020-04732-z

130. Pin A, Tesser A, Pastore S, Moressa V, Valencic E, Arbo A, et al. Biological and clinical changes in a pediatric series treated with off-label JAK inhibitors. Int J Mol Sci. 2020;21(20):7767. doi: 10.3390/ijms21207767

131. Chuprin J, McCormack L, Richmond JM, Rashighi M. Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: An update. Expert Rev Clin Immunol. 2022;18(3):263-272. doi: 10.1080/1744666X.2022.2047022


Рецензия

Для цитирования:

Каледа М.И., Никишина И.П. Проблемы системных заболеваний соединительной ткани детского возраста в исторической перспективе. Научно-практическая ревматология. 2023;61(6):639-649. https://doi.org/10.47360/1995-4484-2023-639-649

For citation:

Kaleda M.I., Nikishina I.P. Problems of systemic connective tissue diseases of childhood in historical perspective. Rheumatology Science and Practice. 2023;61(6):639-649. (In Russ.) https://doi.org/10.47360/1995-4484-2023-639-649

Просмотров: 739


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)
создано и поддерживается NEICON
(лаборатория Elpub)